Teva Pharma (TEVA) Tops Q1 EPS by 17c, Revenues Beat; Offers FY20 EPS/Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to Teva Pharma (TEVA) Tops Q1 EPS by 17c, Revenues Beat; Offers FY20 EPS/Revenue Guidance

Teva Reports First Quarter 2020 Financial Results

May 7, 2020 7:00 AM EDT

Revenues of $4.4 billion GAAP diluted EPS of $0.06 Non-GAAP diluted EPS of $0.76 Free cash flow of $551 million Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2020.

This press release features multimedia. View the full release here:... More